A743C747-1A0E-411A-BE19-027558A02AB3.png
The Odyssey Group International Sports Advisory Board Including Three Super Bowl MVPs will Appear on “Banfield”  to Discuss Concussion Treatments
July 27, 2021 08:30 ET | Odyssey Group International
IRVINE, CA, July 27, 2021 (GLOBE NEWSWIRE) --  Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique,...
logo-brainhq-hi-res-hori.png
Study: New Effective Way to Address Mild Traumatic Brain Injury via Telehealth
July 27, 2021 04:00 ET | Posit Science
SAN FRANCISCO, July 27, 2021 (GLOBE NEWSWIRE) -- A study conducted at five military and Veterans’ hospitals has identified the first effective and highly-scalable intervention to address cognitive...
A743C747-1A0E-411A-BE19-027558A02AB3.png
Odyssey Group International, Inc. Provides Notice of Annual Meeting of Stockholders
July 26, 2021 08:32 ET | Odyssey Group International
IRVINE, CA, July 26, 2021 (GLOBE NEWSWIRE) --  Odyssey Group International, Inc. (OTCQB: ODYY) ("ODYY" or "the Company"), Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"),...
A743C747-1A0E-411A-BE19-027558A02AB3.png
Odyssey Group International Reports Achieving Drug Safety Standards for Clinical Trials of its Drug for Treating Concussion
June 29, 2021 08:30 ET | Odyssey Group International
IRVINE, CA, June 29, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique,...
Logo.png
Oculogica’s New Patent Opens Potential for a CTE Test for Live Subjects
June 24, 2021 09:30 ET | Oculogica, Inc.
NEW YORK, June 24, 2021 (GLOBE NEWSWIRE) -- Oculogica, a leader in concussion diagnosis and categorization, with the only FDA-cleared technology that aids in the diagnosis of concussion without the...
A743C747-1A0E-411A-BE19-027558A02AB3.png
Odyssey Group International to Present at LD Micro Virtual Investor Conference 
June 08, 2021 07:00 ET | Odyssey Group International
IRVINE, CA, June 08, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTCQB: ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique,...
A743C747-1A0E-411A-BE19-027558A02AB3.png
Odyssey Group International Announces Successful Completion of Their Novel Nano-Particle Drug Formulation for Treating Concussion
June 02, 2021 07:30 ET | Odyssey Group International
Irvine, CA, June 02, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique,...
A743C747-1A0E-411A-BE19-027558A02AB3.png
Odyssey Group International Announces Successful Toxicology Studies for its Concussion Drug
May 26, 2021 07:29 ET | Odyssey Group International
IRVINE, CA, May 26, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique,...
A743C747-1A0E-411A-BE19-027558A02AB3.png
Odyssey Group International, Inc. Schedules Annual Meeting of Stockholders
May 24, 2021 08:00 ET | Odyssey Group International
IRVINE, CA, May 24, 2021 (GLOBE NEWSWIRE) -- – Odyssey Group International, Inc. (OTCQB: ODYY) ("ODYY" or "the Company"), Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"),...
A743C747-1A0E-411A-BE19-027558A02AB3.png
Odyssey Group International Announces Completion of Novel Device for Nasal Delivery of Concussion Drug Candidate
May 19, 2021 08:00 ET | Odyssey Group International
IRVINE, CA, May 19, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique,...